市場調查報告書
商品編碼
1466695
支架市場:按類型、材料、交付方式、最終用戶分類 - 2024-2030 年全球預測Stents Market by Type (Coronary Stents, Peripheral Vascular Stents, Prostatic Stents), Material (Biomaterials, Metallic Stents), Mode of Delivery, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年支架市場規模為129.9億美元,預計2024年將達到139.5億美元,2030年將達到215.7億美元,複合年成長率為7.51%。
支架被插入阻塞的途徑中,以打開心臟中的途徑,例如供應富氧血液的薄弱或狹窄的動脈。支架由塑膠或金屬製成,並塗上藥物,可防止阻塞的動脈閉合。與先進的 DES 和先進的生物可吸收支架的引入相比,留置技術比傳統的球囊血管成形術越來越受青睞。由於心血管疾病盛行率的上升、老年人口的增加以及對微創手術的日益偏好,對支架的需求正在增加。然而,支架系統召回和與支架相關的風險的快速增加可能會對市場成長產生負面影響。另一方面,新支架設計的推出和監管機構產品核可預計將增加醫療機構對支架的採用。
主要市場統計 | |
---|---|
基準年[2023] | 129.9億美元 |
預測年份 [2024] | 139.5億美元 |
預測年份 [2030] | 215.7億美元 |
複合年成長率(%) | 7.51% |
類型:全球範圍內需要置入冠狀動脈支架的冠狀動脈疾病發生率較高
冠狀動脈支架用於打開阻塞的心臟動脈,在冠狀動脈疾病的治療中發揮重要作用。這些支架因其微創性質而受到青睞,並大大改善了患者的治療效果。裸金屬支架由金屬合金製成,可作為保持冠狀動脈開放的支架。透過血管成形術將支架放入動脈後,支架周圍的動脈會癒合,使其保持開放。藥物釋放型支架代表了支架技術的進步。這些支架塗有藥物,該藥物會緩慢釋放(洗脫)到動脈壁中,以防止疤痕組織生長,從而血管再阻塞。 DES 顯著降低了血管再阻塞的發生率和重複干預的需要,使其成為大多數支架置入置入術的首選。週邊血管支架用於治療周邊動脈疾病(PAD)並針對心臟和大腦以外的動脈。對於控制四肢血流障礙和預防截肢至關重要。隨著人口老化和 PAD 盛行率的增加,需求不斷成長。前列腺支架主要用於緩解良性前列腺增生(BPH)引起的尿路阻塞。血管支架是一種侵入性較小的手術替代方案。血管支架用於血管內治療,以治療腹部或胸部區域的主動脈瘤。與開放性手術相比,血管支架因其恢復時間更快且併發症風險更低而成為首選的微創方法。泌尿系統支架用於在尿路阻塞時確保尿液通過。它對於腎結石和其他泌尿系統疾病的治療至關重要。對泌尿器官系統支架的偏好是因為它們在預防和治療腎衰竭方面的作用。
最終用戶:在政府改善衛生基礎設施努力的支持下,醫院正在世界各地擴張。
門診手術中心 (ASC) 是支架治療的重要場所,通常提供門診服務,重點是擇期手術。 ASC 的特點是效率、成本效益以及為患者提供的便利。 ASC 主要處理較不複雜的冠狀動脈和周邊介入治療。在這些情況下,首選輕量、易於部署且高精度的支架,以最大限度地減少手術和恢復時間。因此,藥物釋放型支架(DES)是 ASC 的首選,因為它們可以降低血管再阻塞的風險。心臟中心是專門從事心臟病診斷和治療的專業機構。這些設施能夠執行各種支架置入操作,包括需要先進基礎設施(例如混合手術室)的複雜手術。這些中心需要多種支架置入選擇,包括生物可吸收血管支架 (BVS) 和生物工程支架,以解決各種冠狀動脈疾病。治療分叉病變和慢性完全閉塞等複雜病例的能力極為重要。醫院是最廣泛的最終用戶部門,具有廣泛的功能。近年來,醫院服務變得更加多樣化,能夠處理大量病例。由於支架的有效性、多功能性和成本效益,醫院越來越青睞支架。此外,為了適應不同的患者群體,對支援各種血管尺寸和病變類型的支架的需求不斷成長。
區域洞察
美洲支架市場的發展得益於成熟的知名製造商的存在,這些製造商提供多樣化的支架產品組合,並不斷升級其研發以滿足醫療需求。近年來,美國食品藥物管理局多次核准藥物釋放型和心臟支架,鼓勵該地區進一步的支架創新。亞太地區是西方國家的主要原料來源地,主要由來自印度、中國和日本的可靠支架製造商主導。該國改善了心血管手術和支架使用的報銷結構,各國政府正在努力為醫療機構提供具有成本效益的支架。在歐洲,由於安全措施和專注於引入生物分解性支架的研究工作,支架市場變得更加標準化。中東地區醫療基礎設施投資大幅增加,成為市場相關人員業務擴張的潛在基地。
FPNV定位矩陣
FPNV定位矩陣對於評估支架市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對支架市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.支架市場的市場規模和預測是多少?
2.支架市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?
3.支架市場的技術趨勢和法規結構是什麼?
4.支架市場主要廠商的市場佔有率是多少?
5.進入支架市場合適的形式或策略手段是什麼?
[194 Pages Report] The Stents Market size was estimated at USD 12.99 billion in 2023 and expected to reach USD 13.95 billion in 2024, at a CAGR 7.51% to reach USD 21.57 billion by 2030.
Stents are inserted into blocked passageways to open passages in the heart, such as weak or narrowed arteries providing oxygen-rich blood. Stents are made of either plastic or metal and are coated with drugs to help prevent blocked arteries from closing. Stenting technology is increasingly preferred over conventional balloon angioplasty due to the introduction of advanced DES and evolving bioresorbable scaffolds. The rising incidence of cardiovascular diseases, the expanding elderly population, and the increasing preference for minimally invasive procedures have created a need for the utilization of stents. However, the surging incidence of recalls of stent systems and the risk associated with the stents may adversely impact the market's growth. Moreover, introducing new stent designs and product approvals from regulatory authorities are expected to increase the adoption of stents by healthcare facilities.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 12.99 billion |
Estimated Year [2024] | USD 13.95 billion |
Forecast Year [2030] | USD 21.57 billion |
CAGR (%) | 7.51% |
Type: High global incidences of coronary diseases necessitating the deployment of coronary stents
Coronary stents are used in procedures to open clogged heart arteries, playing a critical role in the treatment of coronary heart diseases. These stents are preferred for their minimally invasive nature and the significant improvement in patient outcomes they offer. Bare-metal stents are made of a metal alloy and act as a scaffold to keep the coronary artery open. After the stent is placed in the artery during a procedure known as angioplasty, the artery heals around the stent, maintaining the artery in an open position. Drug-eluting stents represent an advancement in stent technology. These stents are coated with a medication that is slowly released (eluted) into the artery wall to prevent scar tissue growth and, subsequently, restenosis. DES have significantly reduced the incidences of restenosis and the need for repeat interventions, making them the preferred choice in most stenting procedures. Peripheral vascular stents serve to treat peripheral artery disease (PAD), targeting arteries outside the heart and brain. They are essential in managing blood flow obstruction in limbs and preventing amputations. With an aging population and rising PAD prevalence, the demand is growing. Prostatic stents are primarily used to provide relief from urinary obstruction caused by benign prostatic hyperplasia (BPH). Their preference stems from being a less invasive alternative to surgery for patients unable or unwilling to undergo traditional procedures. Stent grafts are used in endovascular procedures to treat abdominal and thoracic aortic aneurysms. They are preferred due to their minimally invasive approach, which reduces recovery time and risk of complications compared to open surgery. Urinary stents are employed to ensure the passage of urine in cases of obstructions in the urinary tract. They are crucial in the management of kidney stones and other urological conditions. The preference for urinary stents lies in their role in preventing or treating renal failure.
End-User: Expansion of hospitals across the world supported by government initiatives for improving healthcare infrastructure
Ambulatory surgical centers (ASCs) represent a critical setting for stent procedures, offering outpatient services that typically focus on elective surgeries. ASCs are characterized by their efficiency, cost-effectiveness, and the convenience they offer to patients. ASCs primarily deal with less complex coronary and peripheral interventions. The preference for lightweight, easy-to-deploy, and high-precision stents is essential in this environment to minimize operative and recovery time. This makes drug-eluting stents (DES) highly favored in ASCs for their reduced risk of restenosis. Cardiac centers are specialized facilities focused exclusively on the diagnosis and treatment of heart conditions. They are equipped to perform a diverse range of stent placements, including more complex procedures that require advanced infrastructural capabilities, such as hybrid operating rooms. There's a demand for versatile stenting options in these centers, including bioresorbable vascular scaffolds (BVS) and bio-engineered stents, to cater to a diverse range of coronary artery diseases. Capability in treating complex cases, such as bifurcation lesions or chronic total occlusions, is crucial. Hospitals represent the broadest end-user sector, encompassing a wide range of capabilities. The versatility of hospital services and their capacity to manage high-volume cases has grown in recent years. The preference in hospitals leans toward stents that offer a combination of efficacy, versatility, and cost-effectiveness. There is also a notable requirement for stents that support a broad range of vessel sizes and lesion types, accommodating the diverse patient demographic.
Regional Insights
The stent market in the Americas is advanced, driven by the presence of well-established and recognized manufacturers serving a diverse portfolio of stents and constantly upgrading their R&D to keep up with medical requirements. In the past few years, the U.S. Food & Drug Administration has provided multiple approvals for drug-eluting and cardiac stents, supporting further stent innovation in the region. The Asia-Pacific region is a mass provider of raw materials to Western nations and is occupied by trusted stent producers across India, China, and Japan. The country observes an improved reimbursement structure for heart surgeries and stent usage, and governments are working toward offering cost-effective stents to healthcare facilities. Europe has a more standardized stent market characterized by safety initiatives and research activities focused on introducing biodegradable stents. The Middle East region witnesses an exponential increase in investments in healthcare infrastructure advancements, creating the region a potential base for company expansion for market players.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Stents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Stents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alvimedica, Andramed GmbH, Arterius Limited, B. Braun SE, Balton Sp. z o. o., Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC, Elixir Medical Corporation, Eurocor Tech GmbH, Integer Holdings Corporation, KYOTO MEDICAL PLANNING Co., Ltd., Lepu Medical Technology(Beijing)Co., Ltd., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Mitra Industries Pvt. Ltd., Nano Therapeutics Pvt. Ltd., QMD, REVA Medical, LLC, Rontis AG, Scitech Medical Products SA, SLTL Group, Stryker Corporation, Terumo Corporation, Veryan Medical Ltd., and W. L. Gore & Associates, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Stents Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stents Market?
3. What are the technology trends and regulatory frameworks in the Stents Market?
4. What is the market share of the leading vendors in the Stents Market?
5. Which modes and strategic moves are suitable for entering the Stents Market?
TABLE 4